Langerhans Cell Histiocytosis

Langerhans CellHistiocytosis (LCH) is an uncommon disorder in which abnormal Langerhans cells accumulate in tissues and cause inflammation or organ damage. It can occur at any age but is more frequently diagnosed in children and young adults. The condition ranges from a single affected site to multisystem disease.

LCH commonly involves the bones, skin, lymph nodes, lungs, liver, spleen, or bone marrow. Bone lesions may cause localized pain, swelling, or fractures, while skin involvement can produce scaly rashes or persistent lesions. Some patients develop excessive thirst and urination when the pituitary region is affected. Symptoms depend on the organs involved and may include fatigue, fever, weight loss, cough, or recurrent infections.

Diagnosis usually combines clinical assessment, imaging, blood tests, and tissue biopsy. Identifying characteristic cells and specific markers helps confirm the disease. Molecular testing may also detect changes such as BRAF mutations.

Treatment is individualized according to disease severity and location. Limited disease may be managed with local therapy, while multisystem LCH can require systemic medicines, targeted therapies, or chemotherapy. Regular monitoring is important because disease activity and long-term complications can vary considerably. With appropriate diagnosis and treatment, many patients achieve good disease control, although some require prolonged follow-up.